Literature DB >> 27046314

Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Carolyn I Rodriguez1,2, Michael Wheaton, Jordana Zwerling, Shari A Steinman, Danae Sonnenfeld, Hanga Galfalvy, Helen Blair Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27046314      PMCID： PMC5544939          DOI： 10.4088/JCP.15l10138

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  16 in total

1.  Maximizing exposure therapy: an inhibitory learning approach.

Authors:  Michelle G Craske; Michael Treanor; Christopher C Conway; Tomislav Zbozinek; Bram Vervliet
Journal:  Behav Res Ther       Date:  2014-05-09

Review 2.  Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections.

Authors:  Ronald S Duman
Journal:  Depress Anxiety       Date:  2014-03-10       Impact factor: 6.505

Review 3.  D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse.

Authors:  Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2014-03       Impact factor: 6.505

4.  Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.

Authors:  D L Murphy; E A Mueller; J L Hill; T J Tolliver; F M Jacobsen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.

Authors:  David F Tolin; Jonathan S Abramowitz; Gretchen J Diefenbach
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

6.  Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.

Authors:  B D Greenberg; J Benjamin; J D Martin; D Keuler; S J Huang; M Altemus; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1998-12       Impact factor: 4.530

7.  Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder.

Authors:  Ana M Abrantes; David R Strong; Amy Cohn; Amy Y Cameron; Benjamin D Greenberg; Maria C Mancebo; Richard A Brown
Journal:  J Anxiety Disord       Date:  2009-06-24

8.  Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Authors:  Erinn S Gideons; Ege T Kavalali; Lisa M Monteggia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853
View more
  15 in total

Review 1.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study.

Authors:  Omer Linkovski; Michael G Wheaton; Jordana Zwerling; Zagaa Odgerel; Peter van Roessel; Maria Filippou-Frye; Anthony Lombardi; Brianna Wright; Shari A Steinman; Helen Blair Simpson; Francis Lee; Carolyn I Rodriguez
Journal:  J Clin Psychopharmacol       Date:  2019 Jan/Feb       Impact factor: 3.153

3.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

4.  Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.

Authors:  Carolyn I Rodriguez; Jordana Zwerling; Eyal Kalanthroff; Hanyang Shen; Maria Filippou; Booil Jo; Helen Blair Simpson; Ronald M Burch; Joseph R Moskal
Journal:  Am J Psychiatry       Date:  2016-12-01       Impact factor: 18.112

Review 5.  Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Authors:  Samuel T Wilkinson; Paul E Holtzheimer; Shan Gao; David S Kirwin; Rebecca B Price
Journal:  Biol Psychiatry       Date:  2018-09-20       Impact factor: 13.382

6.  Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.

Authors:  Thomas G Adams; Michael H Bloch; Christopher Pittenger
Journal:  J Clin Psychopharmacol       Date:  2017-04       Impact factor: 3.153

Review 7.  Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Authors:  Sandra J Drozdz; Akash Goel; Matthew W McGarr; Joel Katz; Paul Ritvo; Gabriella F Mattina; Venkat Bhat; Calvin Diep; Karim S Ladha
Journal:  J Pain Res       Date:  2022-06-15       Impact factor: 2.832

8.  Adjunct treatment with ketamine enhances the therapeutic effects of extinction learning after chronic unpredictable stress.

Authors:  Denisse Paredes; Anna R Knippenberg; Sarah E Bulin; Lydia J Keppler; David A Morilak
Journal:  Neurobiol Stress       Date:  2022-07-08

Review 9.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

10.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.